Last updated on July 2019

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy


Brief description of study

This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.

Detailed Study Description

This study is a randomized, double-blind, placebo-controlled, 72-week study, followed by a 72-week open-label period. The purpose is to characterize the long-term effects of ataluren-mediated dystrophin restoration on disease progression. Participants will be randomized in a 1:1 ratio to ataluren or placebo. Participants will receive blinded study drug three times daily (TID) at morning, midday, and evening for 72 weeks, after which all participants will receive open-label ataluren for an additional 72 weeks (144 weeks in total). Study assessments will be performed at clinic visits every 12 weeks during the double-blind period and every 24 weeks during the open-label period. The total sample size of ~250 subjects will include ~160 subjects who meet the criteria for inclusion in the primary analysis population (age 7 to 16 years old, baseline six minute walk distance (6MWD) greater than or equal to (>=) 300 meters, supine to stand >= 5 seconds). The study will be conducted in the United States and other countries around the world.

Clinical Study Identifier: NCT03179631

Find a site near you

Start Over

Yale New Haven Hospital

New Haven, CT United States
  Connect »

Queen Mary Hospital

Hong Kong, Hong Kong
  Connect »

University Of Utah

Salt Lake City, UT United States
  Connect »

Texas Children's Hospital

Houston, TX United States
  Connect »

Seattle Children's Hospital

Seattle, WA United States
  Connect »

University of Minnesota

Minneapolis, MN United States
  Connect »

Prevea Clinic, Inc

Green Bay, WI United States
  Connect »

Phoenix Childrens Hospital

Phoenix, AZ United States
  Connect »

Cook Childrens Medical Center

Fort Worth, TX United States
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.